ORIGINAL ARTICLE
Neurol Med Chir (Tokyo) 53, 467¿473, 2013
Risk Assessment for Venous Thromboembolism in Patients
With Neuroepithelial Tumors: Pretreatment
Score to Identify High Risk Patients
Tomohiro KAWAGUCHI,1 Toshihiro KUMABE,1 Masayuki KANAMORI,1
Ryuta SAITO,1 Yoji YAMASHITA,1 Yukihiko SONODA,1 and Teiji TOMINAGA1
1Department
of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi
Abstract
The independent risk factors for venous thromboembolism (VTE) were investigated in patients with
neuroepithelial tumor to establish a risk score for VTE. Our prospective study enrolled 395 hospitalized
cases with neuroepithelial tumors. All cases underwent measurement of serum D-dimer concentration
and neurological examination on admission. Serum D-dimer concentration was measured on days 1, 3,
and 7 after surgery and weekly during follow up in patients who underwent surgery, and once a week
during follow up in patients without surgery. Fourteen clinical parameters were evaluated as indicators
of VTE, and among them, age, body-mass index, chemotherapy, radiation therapy, corticosteroid usage,
pretreatment serum D-dimer concentration, paresis of the lower extremity (manual muscle test: MMT),
performance status, and World Health Organization grade of the tumor achieved statistical significance. Multivariable logistic regression analysis demonstrated age À65 years, corticosteroid usage,
paresis of the lower extremity, and serum D-dimer concentration over 1.0 mg/dl were independent factors. Total risk score was defined as the total of the scores for risk factors assigned based on the adjusted
odds ratio: pretreatment serum D-dimer concentration over 1.0 mg/dl (2 points), and age over 65 years
old, paresis of the lower extremity of MMT Ã2, and corticosteroid usage (1 point each). Rates of VTE
were 2.0% in the low risk (total score 0 or 1), 14.8% in the intermediate risk (total score 2 or 3), and
51.9% in the high risk groups (total score = 4 or 5). This pretreatment risk score for VTE might be useful
to identify patients who would benefit from thromboprophylaxis.
Key words:
venous thromboembolism,
glioma,
D-dimer,
Introduction
risk categorization
like other cancers; patients with glioma sometimes
develop neurological deficits, such as hemiparesis;
chemotherapy, radiation therapy, and corticosteroid
usage are sometimes included as postoperative treatments, which result in longer hospitalization; and
disease progression sometimes reduces the performance status and activity of daily living. Therefore,
glioma patients present with different risks of VTE
compared to patients with other cancers or medical
diseases.
The present study tried to identify the specific risk
factors for VTE in patients with neuroepithelial
tumor, by scoring of the predisposing risks.
Venous thromboembolism (VTE) remains a complication carrying high risks of morbidity and mortality in patients undergoing surgery or medical treatment. Specific risk factors have been identified in
various populations,4,5,19,25,30,32,34) but these risk factors somewhat depend on the clinical conditions,
such as cancer or orthopedic surgery, so a generalized risk assessment model might be hard to establish. High incidences of VTE are associated with
brain tumors, and the highest incidence with malignant glioma,1,33,36) variously reported as 20–30% over
the course of the disease.12,15,20,27,31,37) Patients with
glioma are considered to have specific conditions as
follows: glioma carries a high risk disease of VTE,
Received July 12, 2012;
Accepted August 9, 2012
Author's present address: T. Kumabe, MD, Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
467
T. Kawaguchi et al.
468
Methods
This study prospectively enrolled patients with
neuroepithelial tumors, such as astrocytic tumors,
oligodendroglial tumors, ependymal tumors, other
neuroepithelial tumors, and neuronal and mixed
neuronal-glial tumors. All patients were admitted
for treatment, including surgical resection, biopsy,
chemotherapy, or radiation therapy at Tohoku University Hospital between January 2007 and July
2011. Numbers of patients and their hospitalizations
were 253 and 395, respectively. In this study, the 395
hospitalized cases were analyzed. Some of them
have been reported elsewhere.23) The histological diagnosis was based on the new World Health Organization (WHO) classification.26) Patients with
metastatic brain tumor, non-neuroepithelial tumor
such as meningioma or germ cell tumor, and spinal
cord tumor, and patients under the age of 18 years
were excluded. Informed consent was obtained
from each patient or guardian on admission, and
prior to whole body computed tomography (CT)
with contrast medium or anticoagulant therapy.
Risk factors were selected from earlier reports as
follows4,5,19,25,30,32,34): Age, sex, history of cerebrovascular events, presence of diabetes mellitus (DM),
cancer, obesity (body-mass index: BMI), surgical
treatment, chemotherapy, radiation therapy, any
types and dosage of corticosteroid usage, tumor
histology (WHO grade), paresis of the lower extremity, performance status, and serum D-dimer level on
admission and before treatment including surgery,
chemotherapy, and radiation therapy. These variables were prospectively recorded in a computerized
database for analysis. Imaging findings, including
CT, magnetic resonance imaging, and Doppler
ultrasonography of the lower extremity, were also
recorded.
The patients were treated following the protocol
previously reported.23) The serum D-dimer level was
quantitatively measured on admission, and at 1, 3,
and 7 days after surgical intervention and every
week during follow up in patients who underwent
surgery, including tumor resection and biopsy, and
every week during follow up in patients who did not
undergo surgery. Increased serum D-dimer level exceeding 10.0 mg/dl indicated further examinations
for VTE with Doppler ultrasonography or CT with
contrast medium of the chest, abdomen, and lower
extremities. Both symptomatic and asymptomatic
deep vein thrombosis (DVT) in the lower extremities
or pulmonary embolism were defined as VTE in this
study.
The means and standard deviations (SDs) for each
variable were calculated for the VTE and non-VTE
groups. Age, BMI, and manual muscle test (MMT)
were compared between the 2 groups with the unpaired t test. Performance status and serum D-dimer
level were compared between the 2 groups with the
Mann-Whitney test. Other parameters were compared between the 2 groups with the Fisher's exact
test. Any variable with a p value of º0.20 by univariate analysis was considered a potential independent
variable and was entered into the multivariate logistic regression analysis. Pearson's correlation
coefficients were calculated, and if highly co-linear
factors were both significant, the most easily obtained clinical measure was selected. Multivariate
logistic analysis was then performed on the significant variables for calculation of the quantitative
risk of VTE onset. The p value for selection as an independent variable was set at 0.05. Statistical analyses were performed using Microsoft Excel and
SPSS (IBM Japan, Tokyo).
Point values were assigned to each risk factor
based on the relative adjusted odds ratio, rounded to
the nearest integer. The total risk score for each
patient was calculated as the sum of the point
values. The VTE occurrence rate was calculated for
each risk score group.
Results
The 212 male and 183 female patients were aged
18–89 years (median 53 years). The most frequent
tumor histology was glioblastoma (WHO grade IV).
During the study period, 43 (10.9%) of the 395
patients developed VTE. The clinical characteristics
are summarized in Table 1.
The means and SDs or range for each variable are
given in Table 2. Univariate analysis found significant differences for 9 parameters: age (p º
0.0001), BMI (p = 0.141), chemotherapy (p = 0.143),
radiation therapy (p = 0.100), corticosteroid usage
(p º 0.01), serum D-dimer level (p º 0.0001), paresis
of the lower extremity (MMT) (p º 0.001), performance status (p = 0.003), and WHO grade of the
tumor (p º 0.05).
The 9 significant parameters were further analyzed using multivariate logistic analysis to identify
significance accounting for all relevant variables.
Before performing regression analysis, all parameters were categorized into 2 groups, age (over or under 65 years), BMI (over or under 25 kg/m2), serum
D-dimer level (over or under 1.0 mg/dl), and MMT
(0–2 or 3–5). Pearson's correlation coefficients were
calculated. High correlations were seen between
radiation therapy and chemotherapy, WHO grade
and chemotherapy, performance status and MMT,
respectively. Based on them, radiation therapy,
Neurol Med Chir (Tokyo) 53, July, 2013
VTE Risk Score in Glioma Patients
Table 1 Baseline demographic characteristics of the
total study population (n = 395)
Characteristic
Number of cases
Age, range (median), years
Sex
female
male
WHO grade IV
glioblastoma
gliosarcoma
WHO grade III
anaplastic astrocytoma
anaplastic oligodendroglioma
anaplastic oligoastrocytoma
anaplastic ganglioglioma
anaplastic ependymoma
gliomatosis cerebri
glioneuronal tumor
WHO grade II
diffuse astrocytoma
oligodendroglioma
oligoastrocytoma
ependymoma
pleomorphic xanthoastrocytoma
glioneuronal tumor
WHO grade I
pilocytic astrocytoma
ganglioglioma
18–89 (53)
183
212
200
199
1
97
43
32
11
4
2
3
2
68
28
23
9
4
3
1
23
13
10
WHO: World Health Organization.
Table 2
(VTE)
%
46.3
53.7
50.6
50.4
0.3
24.6
10.9
8.1
2.8
1.0
0.5
0.8
0.5
17.2
7.1
5.8
2.3
1.0
0.8
0.3
5.8
3.3
2.5
469
WHO grade, and performance status were excluded.
Finally, logistic regression analysis was performed
for age, BMI, chemotherapy, corticosteroid usage,
MMT, and serum D-dimer level. Among them, age,
corticosteroid usage, MMT, and serum D-dimer
level were identified as independently significant
parameters (Table 3).
Our scoring strategy for each of the risk factors
was intended to assign the total score to a specific
absolute risk of VTE. According to the relative adjusted odds ratio, age À65 years, MMT Ã2, and corticosteroid usage were assigned 1 point, and serum
D-dimer level À1.0 mg/dl was assigned 2 points, because the odds ratio of serum D-dimer level was as
twice as that of age, MMT, and corticosteroid usage
(Table 3). Therefore, the total risk score ranged 0 to
5. Patients with higher score had higher occurrence
of VTE onset. Figure 1 shows a probable logarithmic
relationship between the risk score and the rate of
VTE. The patient population was divided into 3 risk
categories based on the risk score: low risk (total
score 0 or 1), intermediate risk (total score 2 or 3),
and high risk (total score 4 or 5). The rate of VTE was
2.0% in the low risk group, and 14.8% in the intermediate risk group, and much higher at 51.9% in the
high risk group (Fig. 2).
Univariate analysis for all parameters examined in patients with or without venous thromboembolism
Parameter
Demographic parameters
age, mean ± SD, years
male sex
BMI, mean ± SD, kg/m2
Treatment related parameters
surgery
chemotherapy
radiation therapy
corticosteroid usage
Background condition
cancer
cerebrovascular disease
diabetes mellitus
Patient condition
pretreatment serum D-dimer level, median (25%–75%), mg/dl
paresis of lower extremity, mean ± SD, MMT
performance status, median (25%–75%)
WHO grade III or IV
Number of cases
with VTE
(n = 43)
Number of cases
without VTE
(n = 352)
62.1±10.8
21 (48.8%)
20.8±1.6
49.3±15.4
191 (54.3%)
21.6±3.6
º0.0001*
0.521**
0.141*
33
30
23
21
251
204
139
95
0.590**
0.143**
0.100**
º0.01**
(76.7%)
(69.8%)
(53.5%)
(48.8%)
1 (2.3%)
1 (2.3%)
5 (11.6%)
19 (5.4%)
4 (1.1%)
34 (9.7%)
0.710**
0.440**
0.596**
2.80 (1.60–7.25)
3.7±1.4
2.00 (1.00–3.00)
38 (88.4%)
0.70 (0.50–1.10)
4.3±1.0
1.00 (0.00–2.00)
259 (73.6%)
º0.0001***
º0.001*
0.003***
º0.05**
Values determined by *unpaired t test, **Fisher's exact test, or ***Mann-Whitney test.
manual muscle test, SD: standard deviation, WHO: World Health Organization.
Neurol Med Chir (Tokyo) 53, July, 2013
(71.3%)
(58.0%)
(39.5%)
(27.0%)
p Value
BMI: body-mass index, MMT:
T. Kawaguchi et al.
470
Table 3
Multivariate analysis of venous thromboembolism occurrence in patients with neuroepithelial tumors
Parameter
Odds ratio
95% Confidence interval
p Value
Age (À65 years)
BMI (À25.0 kg/m2)
Chemotherapy
Corticosteroid usage
Pretreatment serum D-dimer level (À1.0 mg/dl)
Paresis of lower extremity (MMT Ã2)
3.03
1.30
1.93
2.12
5.99
2.99
1.37–6.69
0.34–5.01
0.8–4.5
1.03–4.37
2.46–14.57
1.22–7.30
0.006
0.70
0.12
0.043
º0.001
0.016
BMI: body-mass index, MMT: manual muscle test.
Fig. 1 Risk score plotted against venous thromboembolism (VTE) rate. The graph indicates a logarithmic
relationship between risk score and rate of VTE occurrence (number of patients with VTE/total number of
patients).
Fig. 2 Three risk groups based on the risk score. Rates
of venous thromboembolism (VTE) occurrence were
2.0% in the low risk (score 0 or 1), 14.8% in the intermediate risk (score 2 or 3), and 51.9% in the high risk
groups (score 4 or 5).
Discussion
The present study identified 4 clinical and laborato-
ry parameters that were independently associated
with the occurrence of VTE: age À65 years, corticosteroid usage, paresis of the lower extremity,
and serum D-dimer concentration À1.0 mg/dl. We
propose a scoring strategy for the prediction of VTE
based on these parameters, which can always be assessed on admission or before starting treatment, so
the scoring strategy is quite simple and easy to introduce in the clinical setting.
All risk factors identified in this study were
proposed in earlier studies.21,24,25,33) Corticosteroid
usage can be thrombogenic because of the increase
in platelet function via activation of factor VIII,28)
and can also induce the hypofibrinolytic state.2)
Therefore, corticosteroid usage is considered as an
independent risk factor for VTE because of these
hypercoagulability and hypofibrinolytic states.35) We
could not assess how the dosage or duration of corticosteroid usage affects the VTE occurrence, because of the relatively small sample size. More such
cases must be documented and analyzed.
Paresis of the lower extremity is known as a risk
factor for VTE. Venous congestion might be occurred, which resulted in DVT. In our series, most
cases with DVT had thrombus in the paretic lower
extremity. In only one case, DVT was detected in the
non-paretic lower extremity. However, the general
activity of this patient was low (performance status
4) because of tumor progression. Immobilization of
the lower extremity is considered to carry high risk
of DVT occurrence.
Serum D-dimer level has a stronger association
with VTE onset. D-dimer is the most reliable blood
marker for VTE, because the serum concentration
immediately increases at the onset of thrombotic
events.8–10,38) In fact, serial D-dimer measurement is
useful not only for early detection of VTE but also
for prediction of VTE occurrence.3,23) Univariate
analysis indicated that tumor WHO histology grade
had a strong correlation with VTE occurrence (p º
0.05). However, this factor was intentionally
dropped from the risk predictive factor for multivariate analysis because strong co-linear effects
Neurol Med Chir (Tokyo) 53, July, 2013
VTE Risk Score in Glioma Patients
were observed between WHO grade and age,
chemotherapy, performance status, and limb paresis, and because we need to predict the risk of VTE
before tumor histology is obtained.
Studies in other settings have shown strong associations between VTE onset and presence of DM,
cancer, or cerebrovascular disease,17,18,22,39) which
were not recognized as independent risk factors in
our study, possibly because the number of patients
with these complications was small. In fact, only 5,
20, and 39 patients had treatment history for
cerebrovascular disease, cancer, and DM, respectively.
The present study found the rate of VTE was
10.9%. One previous prospective study found the
rate of VTE was 13% in patients after elective neurosurgery.1) Another prospective study revealed a
20.8% rate of DVT in glioma patients at 12 months
after surgery.7) The duration of follow up was shorter in our study, but our findings are mostly consistent with previous reports. In our study, patients
with risk scores of 0 or 1 had a VTE rate of 2.0%.
This group was considered to have low risk of VTE,
compared to the general occurrence of VTE reported previously. Patients with risk score of 2 or 3 had
VTE rate of 14.8%. This group was considered to
have intermediate risk of VTE, in the same range as
previous reports.23) In contrast, patients with risk
score of 4 or 5 had remarkably high VTE occurrence
of 51.9%. This group was considered to have high
risk of VTE. Although the number of cases was limited, we recommend that intervention should be considered for patients in the high risk group.
VTE is a leading cause of death in patients with
various conditions, and the risk of VTE in patients
with glioma remains higher than with other malignancies throughout the course of disease.16,21) Therefore, thromboprophylaxis is an important aim of
modern medicine. The prophylactic strategies
should be based on assigning groups of patients to
risk categories. Our result clearly indicates that
patients can be divided into 3 risk groups. Administration of low molecular weight heparin or other antithrombus drugs, such as factor Xa inhibitor, are
presently recommended for patients with high VTE
risk.6,13) Antithrombotic agents are routinely used in
patients undergoing general or orthopedic surgery
and in hospitalized medical patients, but not usually
given in patients with brain tumors because of the
risk for anticoagulant-associated intracranial bleeding, especially in early postoperative period.11,14,29)
To obtain the maximum efficacy with minimum
risk, patient selection for anticoagulant indication is
highly recommended. The present scoring strategy
might be beneficial for this purpose.
Neurol Med Chir (Tokyo) 53, July, 2013
471
Our study has several limitations. This single center study had a relatively small sample size.
Moreover, this study examined the minimum number of parameters. More factors, such as heart
failure, respiratory failure, and recent trauma, were
examined in other reports.5,21) The present study focused on patients with neuroepithelial tumor, which
is considered to be a highly specific condition. Our
scoring strategy should be considered as a diseasespecific model, which is applicable only to patients
with neuroepithelial tumor. This preliminary study
was intended only to develop the risk assessment
score. A more universal study, such as a multicenter
prospective observational study, is recommended to
develop a derivation and validation cohort.
The present study demonstrated that the risk of
VTE in patients with neuroepithelial tumor can be
assessed using a simple risk score model based on 4
parameters. This patient stratification of VTE risk
might be useful to identify patients who would
benefit from thromboprophylaxis.
Conflicts of Interest Disclosure
The authors have no personal financial or institutional interest in any of the drugs, materials, or
devices in the article. All authors have registered online Self-reported COI Disclosure Statement Forms
through the website for JNS members.
References
1)
2)
3)
4)
5)
Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini
M, D'Angelo A, Beltrametti C, Damiani M, Andrioli
GC, Pugliese R, Iorio A, Brambilla G: Enoxaparin
plus compression stockings compared with compression stockings alone in the prevention of venous
thromboembolism after elective neurosurgery. N
Engl J Med 339: 80–85,1998
Athale UH, Chan AK: Thrombosis in children with
acute lymphoblastic leukemia. Part II. Pathogenesis
of thrombosis in children with acute lymphoblastic
leukemia: effects of the disease and therapy. Thromb
Res 111: 199–212, 2003
Ay C, Dunkler D, Simanek R, Thaler J, Koder S,
Marosi C, Zielinski C, Pabinger I: Prediction of
venous thromboembolism in patients with cancer by
measuring thrombin generation: results from the
Vienna Cancer and Thrombosis Study. J Clin Oncol
29: 2099–2103, 2011
Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac
AL, Drach J, Quehenberger P, Wagner O, Zielinski C,
Pabinger I: D-dimer and prothrombin fragment 1 + 2
predict venous thromboembolism in patients with
cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27: 4124–4129, 2009
Barbar S, Noventa F, Rossetto V, Ferrari A, Brando-
472
6)
7)
8)
9)
10)
11)
12)
13)
14)
15)
16)
17)
18)
T. Kawaguchi et al.
lin B, Perlati M, De Bon E, Tormene D, Pagnan A,
Prandoni P: A risk assessment model for the identification of hospitalized medical patients at risk for
venous thromboembolism: the Padua Prediction
Score. J Thromb Haemost 8: 2450–2457, 2010
Becattini C, Lignani A, Agnelli G: New oral anticoagulants for venous thromboembolism: focus on
factor Xa and thrombin inhibitors. Curr Drug Discov
Technol 9: 119–128, 2012
Brandes AA, Scelzi E, Salmistraro G, Ermani M,
Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV: Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective
study. Eur J Cancer 33: 1592–1596, 1997
Brown MD, Lau J, Nelson RD, Kline JA: Turbidimetric D-dimer test in the diagnosis of pulmonary embolism: a metaanalysis. Clin Chem 11: 1846–1853,
2003
Brown MD, Rowe BH, Reeves MJ, Bermingham JM,
Goldhaber SZ: The accuracy of the enzyme-linked
immunosorbent assay D-dimer test in the diagnosis
of pulmonary embolism: a meta-analysis. Ann Emerg
Med 2: 133–144, 2002
Chew HK, Wun T, Harvey D, Zhou H, White RH: Incidence of venous thromboembolism and its effect on
survival among patients with common cancers. Arch
Intern Med 166: 458–464, 2006
Dentali F, Douketis J, Gianni M, Lim W, Crowther
MA: Metaanalysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in
hospitalized medical patients. Ann Intern Med 146:
278–288, 2007
Flinn WR, Sandager GP, Silva MB Jr, Benjamin ME,
Cerullo LJ, Taylor M: Prospective surveillance for
perioperative venous thrombosis: experience in 2643
patients. Arch Surg 131: 472–480, 1996
Galanis T, Thomson L, Palladino M, Merli GJ: New
oral anticoagulants. J Thromb Thrombolysis 31:
310–320, 2011
Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama
CM, Lassen MR, Colwell CW; American College of
Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians
Evidence-Based Clinical Practice Guideline (8th Edition). Chest 133: 381S–453S, 2008
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen
MR, Colwell CW, Ray JG: Prevention of venous
thromboembolism: the Seventh ACCP Conference on
Antithrombotic and Thrombolytic Therapy. Chest
126: 338S–400S, 2004
Gerber DE, Grossman SA, Streiff MB: Management
of venous thromboembolism in patients with primary
and metastatic brain tumors. J Clin Oncol 24:
1310–1318, 2006
Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE,
Colditz GA, Speizer FE, Willett WC, Hennekens CH:
A prospective study of risk factors for pulmonary embolism in women. JAMA 277: 642–645, 1997
Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP,
19)
20)
21)
22)
23)
24)
25)
26)
27)
28)
29)
30)
31)
Kannel WB, McNamara PM, Gherardi G, Feinleib M:
Risk factors for pulmonary embolism. The Framingham Study. Am J Med 74: 1023–1028, 1983
Heinemann LA, Dominh T, Assmann A, Schramm
W, Sch äurmann R, Hilpert J, Spannagl M: VTE Risk
assessment—a prognostic Model: BATER Cohort
Study of young women. Thromb J 3: 5, 2005
Horlander KT, Mannino DM, Leeper KV: Pulmonary
embolism mortality in the United States, 1979–1998:
an analysis using multiple-cause mortality data. Arch
Intern Med 163: 1711–1717, 2003
Jenkins EO, Schiff D, Mackman N, Key NS: Venous
thromboembolism in malignant gliomas. J Thromb
Haemost 8: 221–227, 2010
Kakkar VV, Howe CT, Nicolaides AN, Renney JT,
Clarke MB: Deep vein thrombosis of the leg: is there a
``high risk'' group? Am J Surg 120: 527–530, 1970
Kawaguchi T, Kumabe T, Kanamori M, Nakamura T,
Saito R, Yamashita Y, Sonoda Y, Watanabe M,
Tominaga T: Early detection of venous thromboembolism in patients with neuroepithelial tumor: efficacy of screening with serum D-dimer measurements
and Doppler ultrasonography. J Neurooncol 101:
495–504, 2011
Khorana AA, Francis CW, Culakova E, Kuderer NM,
Lyman GH: Frequency, risk factors, and trends for
venous thromboembolism among hospitalized cancer patients. Cancer 110: 2339–2346, 2007
Khorana AA, Kuderer NM, Culakova E, Lyman GH,
Francis CW: Development and validation of a predictive model for chemotherapy-associated thrombosis.
Blood 111: 4902–4907, 2008
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK:
WHO Classification of Tumours of the Central Nervous System, ed 4. Lyon, IARC, 2007
Nashef SA, Roques F, Michel P, Gauducheau E,
Lemeshow S, Salamon R: European system for
cardiac operative risk evaluation (EuroSCORE). Eur J
Cardiothorac Surg 16: 9–13, 1999
Ozsoylu S, Strauss HS, Diamond LK: Effects of corticosteroids on coagulation of the blood. Nature 195:
1214–1215, 1962
Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli
G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN: PRODIGE: a
randomized placebo-controlled trial of dalteparin
low-molecular-weight heparin thromboprophylaxis
in patients with newly diagnosed malignant glioma. J
Thromb Haemost 8: 1959–1965, 2010
Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson
WG, Zinner MJ, Khuri SF: Multivariable predictors
of postoperative venous thromboembolic events after
general and vascular surgery: results from the patient
safety in surgery study. J Am Coll Surg 204:
1211–1221, 2007
Roques F, Nashef SA, Michel P, Gauducheau E, de
Vincentiis C, Baudet E, Cortina J, David M, Faichney
A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor
PP, Salamon R, Thulin L: Risk factors and outcome
Neurol Med Chir (Tokyo) 53, July, 2013
VTE Risk Score in Glioma Patients
32)
33)
34)
35)
36)
in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur
J Cardiothorac Surg 15: 816–823, 1999
Samama MM, Dahl OE, Quinlan DJ, Mismetti P,
Rosencher N: Quantification of risk factors for
venous thromboembolism: a preliminary study for
the development of a risk assessment tool. Haematologica 88: 1410–1421, 2003
Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D,
Zhou H, White RH: Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.
J Neurosurg 106: 601–608, 2007
Spyropoulos AC, Anderson FA Jr, Fitzgerald G,
Decousus H, Pini M, Chong BH, Zotz RB, Bergmann
JF, Tapson V, Froehlich JB, Monreal M, Merli GJ,
Pavanello R, Turpie AG, Nakamura M, Piovella F,
Kakkar AK, Spencer FA; IMPROVE Investigators:
Predictive and associative models to identify
hospitalized medical patients at risk for VTE. Chest
140: 706–714, 2011
Stassen PM, Derks RP, Kallenberg CG, Stegeman CA:
Venous thromboembolism in ANCA-associated vasculitis—incidence and risk factors. Rheumatology
(Oxford) 47: 530–534, 2008
Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J,
Neurol Med Chir (Tokyo) 53, July, 2013
473
Olson RE: Incidence of venous thromboembolism in
patients hospitalized with cancer. Am J Med 119:
60–68, 2006
37) Stein PD, Henry JW: Prevalence of acute pulmonary
embolism among patients in a general hospital and at
autopsy. Chest 108: 978–981, 1995
38) Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA,
Brant R, Biel RK, Bharadia V, Kalra NK: D-dimer for
the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med
8: 589–602, 2004
39) White RH, Gettner S, Newman JM, Trauner KB,
Romano PS: Predictors of rehospitalization for symptomatic venous thromboembolism after total hip
arthroplasty. N Engl J Med 343: 1758–1764, 2000
Address reprint requests to: Toshihiro Kumabe, MD,
Department of Neurosurgery, Kitasato University
School of Medicine, 1–15–1 Kitasato, Minami–ku,
Sagamihara 252–0374, Japan.
e-mail: kuma@kitasato-u.ac.jp